PSYCH OpenIR  > 中国科学院心理研究所回溯数据库(1956-2010)
Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia
Hong, Xiaohong1,2; Chan, Raymond C. K.1,3; Zhuang, Xihang2; Jiang, Tingyun2; Wan, Xiaona2; Wang, Junqing2; Xiao, Bo2; Zhou, Hanhui2; Jiang, Liyun2; Weng, Bilan2; X. H. Hong; R. C. K. Chan
2009-03-01
Source PublicationSCHIZOPHRENIA RESEARCH
ISSN0920-9964
SubtypeArticle
Volume108Issue:1-3Pages:151-157
AbstractSensory gating deficit, as reflected by P50 suppression, has been demonstrated in schizophrenia. Despite extensive evidence of the irreversible effects of typical neuroleptics on this deficit, recent studies of atypical neuroleptics have produced inconsistent findings on the reversibility of P50 suppression in schizophrenia. As the majority of these studies were limited by either their cross-sectional design or the recruitment of patients on multiple medications, the current Study was designed to examine the effects of different neuroleptic medications on the P50 sensory gating index in patients with first-episode, never-medicated schizophrenia. P50-evoked potential recordings were obtained from 62 normal controls when they entered the study and from 65 patients with first-episode, never-medicated schizophrenia at baseline and after six weeks of different neuroleptic treatments (sulpiride [n=241, risperidone [n=24] and clozapine [n-17]). The first-episode, never-medicated schizophrenia patients had impaired sensory gating relative to the normal controls (mean-94.19% [SD = 61.31%] versus mean=41.22% [SD-33.82%]). The test amplitude S2 was significantly higher in the schizophrenia patients than in the normal controls. The conditioning amplitude S1 and the positive symptom scores were related to the P50 gating ratios in schizophrenia at baseline. There was no change in P50 sensory gating (P>0.10) and a significant improvement in the clinical ratings (P>0.10) after six-week neuroleptic treatment for schizophrenia. P50 sensory gating was not significant for the patients who received sulpiride, risperidone or clozapine at baseline (F=1,074, df = 2, 62, P=0.348)or at endpoint (F=0.441, df=2,62, p=0.646). Our findings indicate that there is P50 sensory gating impairment in first-episode, nevermedicated schizophrenia and that treatment with typical and atypical antipsychotics has no significant impact on such gating in this illness.; Sensory gating deficit, as reflected by P50 suppression, has been demonstrated in schizophrenia. Despite extensive evidence of the irreversible effects of typical neuroleptics on this deficit, recent studies of atypical neuroleptics have produced inconsistent findings on the reversibility of P50 suppression in schizophrenia. As the majority of these studies were limited by either their cross-sectional design or the recruitment of patients on multiple medications, the current Study was designed to examine the effects of different neuroleptic medications on the P50 sensory gating index in patients with first-episode, never-medicated schizophrenia. P50-evoked potential recordings were obtained from 62 normal controls when they entered the study and from 65 patients with first-episode, never-medicated schizophrenia at baseline and after six weeks of different neuroleptic treatments (sulpiride [n=241, risperidone [n=24] and clozapine [n-17]). The first-episode, never-medicated schizophrenia patients had impaired sensory gating relative to the normal controls (mean-94.19% [SD = 61.31%] versus mean=41.22% [SD-33.82%]). The test amplitude S2 was significantly higher in the schizophrenia patients than in the normal controls. The conditioning amplitude S1 and the positive symptom scores were related to the P50 gating ratios in schizophrenia at baseline. There was no change in P50 sensory gating (P>0.10) and a significant improvement in the clinical ratings (P>0.10) after six-week neuroleptic treatment for schizophrenia. P50 sensory gating was not significant for the patients who received sulpiride, risperidone or clozapine at baseline (F=1,074, df = 2, 62, P=0.348)or at endpoint (F=0.441, df=2,62, p=0.646). Our findings indicate that there is P50 sensory gating impairment in first-episode, nevermedicated schizophrenia and that treatment with typical and atypical antipsychotics has no significant impact on such gating in this illness. (C) 2008 Elsevier B.V. All rights reserved.
KeywordSensory gating P50 First-episode schizophrenia
Subject Area精神病学 ; 认知神经科学
Indexed BySCI ; SSCI
Language英语
WOS IDWOS:000264506500019
Citation statistics
Cited Times:34[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.psych.ac.cn/handle/311026/5581
Collection中国科学院心理研究所回溯数据库(1956-2010)
Corresponding AuthorX. H. Hong; R. C. K. Chan
Affiliation1.Chinese Acad Sci, Inst Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Beijing 100101, Peoples R China
2.Shantou Univ, Coll Med, Mental Hlth Ctr, Shantou, Peoples R China
3.Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China
Recommended Citation
GB/T 7714
Hong, Xiaohong,Chan, Raymond C. K.,Zhuang, Xihang,et al. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia[J]. SCHIZOPHRENIA RESEARCH,2009,108(1-3):151-157.
APA Hong, Xiaohong.,Chan, Raymond C. K..,Zhuang, Xihang.,Jiang, Tingyun.,Wan, Xiaona.,...&R. C. K. Chan.(2009).Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.SCHIZOPHRENIA RESEARCH,108(1-3),151-157.
MLA Hong, Xiaohong,et al."Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia".SCHIZOPHRENIA RESEARCH 108.1-3(2009):151-157.
Files in This Item:
File Name/Size DocType Version Access License
Hong-2009-Neurolepti(270KB) 限制开放--View Application Full Text
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Hong, Xiaohong]'s Articles
[Chan, Raymond C. K.]'s Articles
[Zhuang, Xihang]'s Articles
Baidu academic
Similar articles in Baidu academic
[Hong, Xiaohong]'s Articles
[Chan, Raymond C. K.]'s Articles
[Zhuang, Xihang]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Hong, Xiaohong]'s Articles
[Chan, Raymond C. K.]'s Articles
[Zhuang, Xihang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Hong-2009-Neuroleptic effects.pdf
Format: Adobe PDF
This file does not support browsing at this time
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.